KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

BeOne Medicines (ONC) Net Income towards Common Stockholders: 2014-2024

Historic Net Income towards Common Stockholders for BeOne Medicines (ONC) over the last 11 years, with Dec 2024 value amounting to -$644.8 million.

  • BeOne Medicines' Net Income towards Common Stockholders rose 202.88% to $124.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $68.5 million, marking a year-over-year increase of 107.97%. This contributed to the annual value of -$644.8 million for FY2024, which is 26.87% up from last year.
  • Latest data reveals that BeOne Medicines reported Net Income towards Common Stockholders of -$644.8 million as of FY2024, which was up 26.87% from -$881.7 million recorded in FY2023.
  • In the past 5 years, BeOne Medicines' Net Income towards Common Stockholders registered a high of -$644.8 million during FY2024, and its lowest value of -$2.0 billion during FY2022.
  • Moreover, its 3-year median value for Net Income towards Common Stockholders was -$881.7 million (2023), whereas its average is -$1.2 billion.
  • As far as peak fluctuations go, BeOne Medicines' Net Income towards Common Stockholders tumbled by 68.46% in 2020, and later skyrocketed by 56.00% in 2023.
  • BeOne Medicines' Net Income towards Common Stockholders (Yearly) stood at -$1.6 billion in 2020, then grew by 10.49% to -$1.5 billion in 2021, then crashed by 37.45% to -$2.0 billion in 2022, then soared by 56.00% to -$881.7 million in 2023, then climbed by 26.87% to -$644.8 million in 2024.